Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma

Eur J Haematol. 2023 Mar;110(3):296-304. doi: 10.1111/ejh.13905. Epub 2022 Dec 4.

Abstract

Long-term disease control in multiple myeloma (MM) is typically an unmet medical need, and most patients experience multiple relapses. Fluorescence in situ hybridization (FISH) is the standard technique to detect chromosomal abnormalities (CAs), which are important to estimate the prognosis of MM and the allocation of risk adapted therapies. In advanced stages, the importance of CAs needs further investigation. From 148 MM patients, two or more paired samples, at least one of which was collected at relapse, were analyzed by FISH. Using targeted next-generation sequencing, we molecularly investigated samples harboring relapse-associated CAs. Sixty-one percent of the patients showed a change in the cytogenetic profile during the disease course, including 10% who acquired high-risk cytogenetics. Amp(1q) (≥4 copies of 1q21), driven by an additional increase in copy number in patients who already had 3 copies of 1q21, was the most common acquired CA with 16% affected patients. Tetraploidy, found in 10% of the samples collected at the last time-point, was unstable over the course of the disease and was associated with TP53 lesions. Our results indicate that cytogenetic progression is common in relapsed patients. The relatively high frequency of amp(1q) suggests an active role for this CA in disease progression.

Keywords: chromosome aberrations; multiple myeloma; recurrence; tetraploidy.

MeSH terms

  • Adenine Phosphoribosyltransferase* / genetics
  • Chromosome Aberrations
  • Humans
  • In Situ Hybridization, Fluorescence
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / pathology
  • Neoplasm Recurrence, Local
  • Prognosis
  • Tetraploidy*

Substances

  • Adenine Phosphoribosyltransferase
  • TP53 protein, human